Arjun Goyal - 24 Jun 2026 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Reporting relationship: Director
Issuer ticker: CNTA
Reported as of: 24 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Jun 2026, 16:15:58 UTC
Prior SEC filing: 17 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Raphael Deferiere, attorney-in-fact

Key filing fact

Arjun Goyal filed Form 4 for Centessa Pharmaceuticals plc (CNTA) on 24 Jun 2026.

Key facts

This page summarizes Arjun Goyal's Form 4 filing for Centessa Pharmaceuticals plc (CNTA).
4 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 24 Jun 2026, 16:15.

Change

Previous filing in this sequence was filed on 17 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001861844 Primary reporting owner

GOYAL ARJUN

Relationship: Director
Address: C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY RD, ALTRINCHAM, CHESHIRE, UNITED KINGDOM
Signature: /s/ Raphael Deferiere, attorney-in-fact
Signature date: 24 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CNTA transaction

Ordinary Shares

Disposed to Issuer

Transaction value
Shares: -462,585
Change %: -100%
Price
Shares after: 0
Date: 24 Jun 2026
Ownership: See footnote
Footnotes: F1, F2, F3, F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CNTA transaction Derivative

Share Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -64,570
Change %: -100%
Price
Shares after: 0
Date: 24 Jun 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 64,570
Exercise price: $22.55
Footnotes: F1, F2, F6

CNTA transaction Derivative

Share Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -48,000
Change %: -100%
Price
Shares after: 0
Date: 24 Jun 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 48,000
Exercise price: $4.87
Footnotes: F1, F2, F6

CNTA transaction Derivative

Share Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -40,000
Change %: -100%
Price
Shares after: 0
Date: 24 Jun 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 40,000
Exercise price: $12.43
Footnotes: F1, F2, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Arjun Goyal is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 6 footnotes

Footnote F1

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Footnote F2

On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement").

Footnote F3

At the effective time of the Scheme of Arrangement (the "Effective Time"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the "Cash Consideration"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a "CVR") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS.

Footnote F4

(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Person.

Footnote F5

Shares held by Vinyanshu Ventures LLC, an entity controlled by the Reporting Person. The Reporting Person disclaims beneficial ownership of the shares reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16"), except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.

Footnote F6

Pursuant to the Transaction Agreement at the Effective Time, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of the Cash Consideration over the per-share exercise price of such option, without interest and less applicable withholding taxes, and (ii) one CVR per underlying Ordinary Share, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time.

SEC remarks

Exhibit 24.2 - Substitute Power of Attorney